KELLY MILBURN: Open Payments
NPI 1366128621 · DANVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,927 in 115 payments from 18 companies in 2025. Trend: 2023 $535 · 2024 $1,543 · 2025 $1,927
Food & beverage: $1,927
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 10 | $255 |
| ABBVIE INC. | 18 | $242 |
| E.R. Squibb & Sons, L.L.C. | 12 | $206 |
| Otsuka America Pharmaceutical, Inc. | 9 | $168 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $154 |
| Janssen Pharmaceuticals, Inc | 7 | $150 |
| Alkermes, Inc. | 7 | $136 |
| Axsome Therapeutics, Inc. | 7 | $124 |
| Biogen, Inc. | 4 | $67 |
Products named: FANAPT, VRAYLAR, COBENFY, CAPLYTA, TRINTELLIX, INVEGA SUSTENNA, REXULTI, Auvelity.
Industry payments across KY — which companies pay providers there.
